Sign in Subscribe
Cancer research

Elpis Biopharmaceuticals Partners with National Cancer Centre Singapore to Develop Bispecific Armored CAR-T Therapies

Strategic Insights

— 2 min read

Elpis Biopharmaceuticals, a clinical-stage cell therapy company, has announced a partnership with the National Cancer Centre Singapore (NCCS) to support collaborative cell therapy research and clinical trials for the treatment of various cancers, including colorectal, pancreatic, and ovarian cancers. The partnership aims to accelerate the development of next-generation cell therapies by combining Elpis's proprietary technologies with NCCS's clinical expertise and access to clinical trial infrastructure.

Key Takeaways:

  • Elpis Biopharmaceuticals and National Cancer Centre Singapore (NCCS) have signed a Memorandum of Understanding (MOU) to support collaborative cell therapy research and clinical trials for cancer treatment.
  • The partnership will focus on developing bispecific armored CAR-T cell therapies for solid tumors, including colorectal, pancreatic, and ovarian cancers.
  • Elpis will contribute clinically validated technologies, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, to drive the development of next-generation cell therapies.
  • NCCS will contribute its expertise in clinical research and access to clinical trial infrastructure to support the evaluation of novel cell therapy candidates.
  • The collaboration will support the development of bispecific armored CAR-T cell therapies for solid tumors, while Elpis's global leading mRNA display technology will support NCCS in the rapid discovery of human antibodies to novel targets and enable novel modalities to cell therapy and beyond.
  • The partnership reflects Elpis's commitment to rapidly advancing innovative immunotherapies from discovery to clinical development through to regulatory review and saving patients' lives.
  • Elpis's global clinical trials of EPC-002 and EPC-003 are already investigating the company's technologies, with the goal of expanding their translational relevance across multiple tumor types.
  • Plans are underway for Elpis to establish a laboratory space at NCCS and co-share equipment to enable more integrated and efficient collaboration.

Statistics:

  • The partnership aims to accelerate the development of next-generation cell therapies for cancer treatment.
  • Elpis's global leading mRNA display technology supports NCCS in the rapid discovery of human antibodies to novel targets and enables novel modalities to cell therapy and beyond.
  • The collaboration will focus on developing bispecific armored CAR-T cell therapies for solid tumors, including colorectal, pancreatic, and ovarian cancers.
  • Elpis's clinically validated technologies, including multi-mechanism armor, bispecific targeting antibodies, cytokine cocktails, and a rapid mRNA display discovery engine, will drive the development of next-generation cell therapies.
  • Elpis's global clinical trials of EPC-002 and EPC-003 are already investigating the company's technologies, with the goal of expanding their translational relevance across multiple tumor types.

Sources:

  • "Elpis Biopharmaceuticals, National Cancer Centre Singapore Sign Memorandum of Understanding to Develop Bispecific Armored CAR-T Therapies for Solid Tumors." NewsRx, 2025.

Read more